Drug Trial Radar · NCT07035990
Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jul 23, 2025
Primary completion
Mar 23, 2026
Study completion Mar 23, 2026
Sponsor
- Lead sponsor
- Sionna Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary modulators SION-2222 and SION-109 in healthy participants.
Conditions
- Cystic Fibrosis (CF)
Interventions
SION-451Drug
* Pharmaceutical form: tablet * Route of administration: oral
SION-2222Drug
* Pharmaceutical form: capsule * Route of administration: oral
SION-109Drug
* Pharmaceutical form: tablet * Route of administration: oral
Placebo SION-451Drug
Placebo matched to SION-451
Placebo SION-2222Drug
Placebo matched to SION-2222
Placebo SION-109Drug
Placebo matched to SION-109
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-109 when administered in combination to healthy participantsTime frame: From Day 1 through day 21
- To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-2222 when administered in combination to healthy participantsTime frame: From Day 1 through day 21
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Brisbane, Queensland, Australia
Nucleus Network
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.